Menquadfi

Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid, the active ingredient in Menquadfi, is a vaccine presented as a powder for suspension for injection for intramuscular use. It induces immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk individuals.

GNH USA supplies Menquadfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, travel clinics and public health programs worldwide.

Menquadfi is used to prevent meningococcal disease caused by serogroup C, a bacterial infection that can lead to severe invasive illness.

- Invasive meningococcal disease (serogroup C): provides active immunity to prevent infection. - Outbreak control in communities: reduces transmission during serogroup C outbreaks. - Travelers to endemic regions: protects individuals traveling to areas with high serogroup C prevalence. - Adolescents and young adults: offers long‑lasting protection in age groups at increased risk.

Menquadfi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness and swelling: localized erythema and edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: transient mild headache. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: infrequent occurrence of convulsive episodes. - Hypotension: sudden drop in blood pressure post‑vaccination.

Before administering Menquadfi, healthcare providers should observe several precautionary measures to ensure safety.

- Allergy assessment: avoid use in individuals with severe hypersensitivity to any vaccine component. - Pregnancy considerations: safety not established; weigh benefits against potential risks. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Concomitant vaccines: separate administration from live vaccines by at least 4 weeks. - Blood product interaction: postpone immunoglobulin therapy for 4 weeks after vaccination. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menquadfi can interact with certain medicines and vaccines, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Live bacterial vaccines: should not be given concurrently; separate by at least 4 weeks. - Immunoglobulin products: avoid administration within 4 weeks before or after vaccination.

Moderate Interactions (Monitor Closely): - Other inactivated vaccines: may be co‑administered but monitor for increased reactogenicity. - Immunosuppressive therapy: may diminish vaccine‑induced immunity; assess antibody response. - Antipyretic agents: can mask fever, a common post‑vaccination sign; use judiciously.